Patents Assigned to GlaxoSmithKline LLC
  • Publication number: 20200327971
    Abstract: Methods and systems for transferring restricted distribution medical products to an over-the-counter general sales environment are provided. Methods and systems of dispensing non-prescription, behind-the-counter medical products from a vending machine in a general sales location are also provided. In some embodiments, methods and systems are provided for dispensing a medical product from a vending machine in a general sales location based, at least in part, on biometric data collected from the purchaser and, in some instances, based on self-selection and/or de-selection criteria, is provided. Further, methods and systems of switching prescription medical products to non-prescription, over-the-counter medical products are provided.
    Type: Application
    Filed: June 24, 2020
    Publication date: October 15, 2020
    Applicant: GLAXOSMITHKLINE, LLC
    Inventors: Daniel Paul Keravich, Richard Alexander McGregor, George Michael Quesnelle
  • Patent number: 10660898
    Abstract: This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3? OH kinase family (hereinafter PI3 kinases), suitably, PI3K?, PI3K?, PI3K?, and/or PI3K?. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3K? selective benzimidazoles compounds for treating cancer.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: May 26, 2020
    Assignee: GLAXOSMITHKLINE LLC
    Inventors: Rosanna Tedesco, Junya Qu, Robert Sanchez, Ralph A. Rivero
  • Patent number: 10590135
    Abstract: The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: March 17, 2020
    Assignee: GLAXOSMITHKLINE LLC
    Inventors: Charles A. Blum, Richard Dana Caldwell, Rebecca Casaubon, Jeremy S. Disch, Ryan Michael Fox, Karsten Koppetsch, William Henry Miller, Pui Yee Ng, Christopher Oalmann, Robert B. Perni, Bruce G. Szczepankiewicz, Brian H. White
  • Patent number: 10478426
    Abstract: This invention relates to novel substituted benzamide according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: November 19, 2019
    Assignee: GLAXOSMITHKLINE LLC
    Inventors: Joelle Lorraine Burgess, Steven David Knight
  • Patent number: 10391717
    Abstract: Aspects of the present invention are directed to a heat sealed packaging wherein the heat seal is along a curved surface. Additional aspects of the present invention are directed to a device for heat sealing a package on a surface that is curved along the direction of force.
    Type: Grant
    Filed: August 27, 2015
    Date of Patent: August 27, 2019
    Assignee: GlaxoSmithKline, LLC
    Inventors: Jason R. Crosby, Gautam Debnath, Roger P. Fager, Peter R. Laubmeier, Curtis Emmanuel Stover
  • Patent number: 10392625
    Abstract: The present invention provides genetically modified Pichia strains wherein at least one nucleic acid sequence encoding a functional gene product and/or at least one nucleic acid sequence necessary for expression of at least one functional gene product in said Pichia strain is genetically modified, wherein said gene product is responsible for proteolysis and/or glycosylation in said genetically modified Pichia strain. In particular, Pichia strains are provided wherein nucleic acid sequence encoding a functional gene product or expression of said gene product are genetically modified: PEP4, PRB1, YPS1, YPS2, YMP1, YMP2, YMP3 and PMT4.
    Type: Grant
    Filed: February 24, 2010
    Date of Patent: August 27, 2019
    Assignee: GlaxoSmithKline LLC
    Inventors: Yong Hwan Jin, James D. Jowett, Alexander H. Taylor, Yuan Zhu
  • Patent number: 10385066
    Abstract: This invention relates to methods for the preparation of a compound which is an inhibitor of acyl coenzyme A: diacylglycerol acyltransferase 1 (DGAT-1).
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: August 20, 2019
    Assignee: GlaxoSmithKline LLC
    Inventors: Mui Cheung, Raghuram Tangirala
  • Patent number: 10357798
    Abstract: The present disclosure provides a device for preventing the fouling of a liquid dispensing nozzle. The end of the dispensing nozzle is placed in a hollow interior of a band carrying the same solvent that is dispensed by the nozzle. The solvent on the band evaporates into a gap between the band and the dispensing nozzle, thus providing a vapor sheath, or environment in the gap, that helps to prevent the fouling of the dispensing nozzle.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: July 23, 2019
    Assignee: GLAXOSMITHKLINE LLC
    Inventors: Allan J. Clarke, Frederick H. Fiesser, James A. McHugh
  • Patent number: 10336711
    Abstract: The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: July 2, 2019
    Assignee: GlaxoSmithKline LLC
    Inventors: Duke M. Fitch, Antony N. Shaw, Kenneth Wiggall
  • Patent number: 10314845
    Abstract: This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3? OH kinase family (hereinafter PI3 kinases), suitably, PI3K?, PI3K?, PI3K?, and/or PI3K?. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3K? selective benzimidazoles compounds for treating cancer.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: June 11, 2019
    Assignee: GlaxoSmithKline LLC
    Inventors: Rosanna Tedesco, Junya Qu, Robert Sanchez, Ralph A. Rivero
  • Patent number: 10286037
    Abstract: The invention is directed to a method for producing a polypeptide composition comprising: combining a polypeptide with a volatile additive to form a liquid mixture and lyophilizing the liquid mixture to obtain a lyophilized polypeptide composition.
    Type: Grant
    Filed: February 9, 2012
    Date of Patent: May 14, 2019
    Assignee: GlaxoSmithKline LLC
    Inventors: James Kranz, Joseph Rinella
  • Publication number: 20190135829
    Abstract: This invention relates to methods for the preparation of a compound which is an inhibitor of acyl coenzyme A: diacylglycerol acyltransferase 1 (DGAT-1).
    Type: Application
    Filed: January 4, 2019
    Publication date: May 9, 2019
    Applicant: GlaxoSmithKline LLC
    Inventors: Mui Cheung, Raghuram Tangirala
  • Patent number: 10238678
    Abstract: The present invention features a method for the treatment of Hepatitis C in a human in need thereof comprising administering a compound of Formulas (II) or (IIB) described herein or a pharmaceutically acceptable salt thereof in combination with one or more alternative Hepatitis C therapeutic agents.
    Type: Grant
    Filed: July 20, 2015
    Date of Patent: March 26, 2019
    Assignee: GlaxoSmithKline LLC
    Inventors: Jill Walker, Christian Voitenleitner
  • Publication number: 20190029591
    Abstract: The present invention is based on the finding that enrichment of D3-creatinine in a urine sample following oral administration of a single defined dose of D3-creatine can be used to calculate total-body creatine pool size and total body skeletal muscle mass in a subject. The invention further encompasses methods for detecting creatinine and D3-creatinine in a single sample. The methods of the invention find use, inter alia, in diagnosing disorders related to skeletal muscle mass, and in screening potential therapeutic agents to determine their effects on muscle mass.
    Type: Application
    Filed: August 8, 2018
    Publication date: January 31, 2019
    Applicants: GLAXOSMITHKLINE LLC, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Marc K. HELLERSTEIN, William J. EVANS
  • Patent number: 10174049
    Abstract: This invention relates to methods for the preparation of a compound which is an inhibitor of acyl coenzyme A: diacylglycerol acyltransferase 1 (DGAT-1).
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: January 8, 2019
    Assignee: Glaxosmithkline LLC
    Inventors: Mui Cheung, Raghuram S. Tangirala
  • Patent number: 10172765
    Abstract: Aspects of the present invention are directed to a metered dose container. The container may comprise a body; a first barrier in contact with a base of the container and extending partially along the vertical axis of the body; a second barrier in contact with a top of the container and extending partially along with vertical axis of the body. The space between the first barrier and the second barrier preferably defines a loading chamber, the space between the second barrier and a front wall of the container preferably defines a dispensing chamber, and the space between a rear wall of the container and the first barrier preferably defines a storage chamber. The base preferably also comprises a depressible portion that can convert the container from a transit mode to a dispensing mode.
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: January 8, 2019
    Assignee: GlaxoSmithKline, LLC
    Inventors: Amit Sabharwal, Sukhdev Singh Saini
  • Patent number: 10117873
    Abstract: Compounds of formula (I): wherein R1 is C1-6alkylamino, C1-6alkoxy, or C3-7cycloalkyloxy; m is an integer having a value of 3 to 6; n is an integer having a value of 0 to 4; and salts thereof are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions for example allergic rhinitis and asthma, the treatment of infectious diseases and cancer, and may also be useful as vaccine adjuvants.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: November 6, 2018
    Assignee: GlaxoSmithKline LLC
    Inventors: Keith Biggadike, Diane Mary Coe, Xiao Qing Lewell, Charlotte Jane Mitchell, Stephen Allan Smith, Naimisha Trivedi
  • Patent number: 10112946
    Abstract: Compound (I), and pharmaceutically acceptable salts thereof, are inducers of human interferon. Certain discrete and particular dosages of Compound (I) may be particularly useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and allergic asthma.
    Type: Grant
    Filed: July 19, 2012
    Date of Patent: October 30, 2018
    Assignee: GlaxoSmithKline LLC
    Inventors: Claire Louise Ambery, Christopher David Edwards
  • Patent number: D830842
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: October 16, 2018
    Assignee: GlaxoSmithKline, LLC
    Inventors: Jamie Trafford Stone, Jonathan Norman Robert Hodges
  • Patent number: D837056
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: January 1, 2019
    Assignee: GlaxoSmithKline, LLC
    Inventors: Jamie Trafford Stone, Jonathan Norman Robert Hodges